⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 3, 2024

Figure 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis

Jack Pengfei Tang Pénélope Lafeuille Alexandru Socolov Sheila S. Diamond Jacob Aptekar Theodore B. Moore Esther H. Nie Mark R. Hanudel Theodore S. Nowicki

View at Publisher

Ask AI

Bookmark

Share

Abstract

Incidence of ICANS in patients stratified by the presence or absence of electrolyte derangements. Kaplan–Meier analyses comparing time to ICANS for patients stratified by the presence or absence of electrolyte derangements including (A) hypophosphatemia, (B) hypokalemia, (C) hypomagnesemia, and (D) hypocalcemia. Shaded area represents the upper and lower bounds of the 95% confidence interval (CI).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tang et al. (2024) studied this question.

synapsesocial.com/papers/68e55ee7e2b3180350efbe29 https://doi.org/10.1158/2767-9764.27160842

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
2Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
3Supplemental Table 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
4Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
5Figure 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024

More related papers

Figure S4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
Figure S3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024